Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

About MaverickNY

Here are my most recent posts

Posts by MaverickNY

A cluster of new developments

Spring is renowned for the season of rejuvenation and new beginnings in nature.

Are we also seeing similar re-birth in novel science developments?

As we head towards the annual ASGCT meeting later this month, there are several important papers I wanted to highlight relevant to the cell and gene therapy niche.

This area is suddenly coming along in leaps and bounds and making great new strides.

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

The road less travelled

The path less travelled can take us in interesting and unknown directions

We often talk about innovation on BSB and how hard it is to blaze a new path in oncology drug development.

Sometimes what it requires is a different way to think about a target or a new approach to modulating a pathway.

In our latest post AACR23 review, we are taking a closer look at more gems from the poster hall and how some companies and researchers are thinking differently.

Taking the road less travelled is inevitably a balance of risk and reward with plenty of challenges to overcome, which by definition is part of what makes oncology new product development such a challenging yet stimulating area…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

ASCO23 Preview 1 – W2W4 in Developmental Therapeutics

Springing between meetings

This time of year always brings a flurry of data across different conferences as we start winding up our AACR coverage, spring forward to the ASCO abstract title drop and prepare for the forthcoming ASGCT meeting.

Of course, much like the weather of late there are always uncertainties involved when looking at abstract titles.

We may know, for example, that certain trials have been announced as positive having met their pre-defined criteria, but as to the exact magnitude of the effect and how much benefit is actually offered in terms of outcomes is another story entirely!

It would be impossible to review all of the meeting in one go, hence we’ll be offering a series of snapshots and discussion highlighting different key topics over the next few weeks.

Here are our notes on the first one in the series…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

AACR23 Insights on gems from the poster halls – Part 1

At AACR annual meetings there is a phenomenal number of posters on display, truly a smorgasbord of up and coming agents and targets relevant to cancer research.

I can still remember the trials and tribulations traveling from the UK to Boston as a PhD student on a limited budget to present a poster at a major US conference, so would like to congratulate all the young researchers with posters at this year’s AACR meeting. Presenting at an international meeting is a big deal and this year was the first time post-pandemic many could easily travel without restriction.

Fishing for gems in the poster halls

With several thousand posters to choose from the selection of what caught our interest is, by definition, subjective.

We’ve chosen to focus on new products in development or novel targets.

In part one of our AACR gems from the poster hall, we have 10 posters from emerging biotech companies with early stage data.

For each poster we’ve highlighted what we liked about the data, what to watch out for, and what our overall impressions were relative to some of the competition.  Not all of them will make it through to phase 3, but some could show some initial promise.

If you haven’t finished your AACR23 trip report and want a few suggestions of what you might have missed or what emerging agents could be highlighted, this post may be for you.

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

AACR23 – Is there an ADC renaissance on the horizon?

Orlando – the AACR annual meeting provides a window into future cancer drug development, and this year’s meeting is no exception.

As AACR23 comes to an end in sunny Orlando, we’re taking a closer look at the next generation of ADC’s in early development and some of the data presented at AACR23.

Companies are always looking for new ways to overcome resistance pathways or provide novel combination strategies. Will the next generation compounds in development lead to a continued renaissance in the ADC field?

There’s certainly plenty to think about if you are a new products or business development professional…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

AACR23 – New is not necessarily better

Orlando – At AACR23 the old adage of “be the first, or be the best” is well and truly on display when it comes to oncology drug development.

This should give heart to companies who break new ground.

Me-too drugs and follow-on innovation, however, has to deliver in terms of enhanced clinical benefit or a much improved toxicity profile.

At AACR23 we’ve already seen a few companies fall a bit short.

New does not always mean better – instead it may well be a case of ‘who dares wins’, to use the motto of the British SAS.

In this latest post we’re continuing our commentary and analysis of data presented at AACR23.

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

AACR23 – is the Florida sun shining on KRAS?

Orlando – AACR23 is in full swing and one of the areas gaining a lot of attention at the meeting is a surfeit of new data on targeting KRAS.

In this post we review some of the key data presented so far, along with commentary from some of the education sessions we’ve covered, which not everyone may have attended.

Can we beat KRAS and, if not, what are the challenges to be overcome? How should we go about this endeavour?  Is it all sun and palm trees in Florida?

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

AACR23 Preview 8 – Keys to success in TPD

The key to success in TPDIn our final AACR Preview ahead of the meeting, we take a look at various protein and molecular glue degraders where we highlight some of the potential areas of interest, as well as some of the challenges the field faces.

We also point to a key variable or measure to watch out for in presentations at this meeting…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

AACR23 Preview 7 – Surfeit of riches

With the rapidly evolving KRAS niche from seemingly intractable therapeutically to a vast array of different MOAs now appearing in company pipelines, you could well be forgiven for thinking of Perry Como singing ‘it’s beginning to look a lot like Christmas.’ 

The sheer number of new agents, novel targets, different MOAs, and even creative combination strategies emerging is making this niche incredibly hard – albeit rewarding – to keep up with.

Every time we post even a mini update there seems to be something new to discuss and the latest review is no different in this respect… prepare to be pleasantly surprised!

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

AACR23 Preview 6 – Taking a closer look at KRAS Part 1

In our latest AACR Preview series we now turn our attention to the evolving KRAS niche of inhibitors and degraders.

It’s not that long ago we only had G12C mutations to talk about in terms of what was considered ‘druggable’ and now we have another mutant (G12D) with at least two agents in the clinic already and more soon to come.

Of course, there are also the pan inhibitors in the mix and these will be covered separately.

For now though, it’s the turn of the selective agents with much more going on than many observers may realise, including some interesting novel developments coming through…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

error: Content is protected !!